LON:SAR - Sareum Stock Price, News, & Analysis

GBX 0.52
0.00 (0.00 %)
(As of 06/18/2019 04:00 PM ET)
Today's Range
0.52
Now: GBX 0.53
0.55
50-Day Range
0.53
MA: GBX 0.62
0.75
52-Week Range
0.45
Now: GBX 0.53
0.95
Volume2.73 million shs
Average Volume6.23 million shs
Market Capitalization£15.10 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Sareum Holdings plc engages in the discovery and development of therapeutic drugs to treat cancer and autoimmune diseases. It develops therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company's product pipeline includes Checkpoint Kinase 1, Aurora+FLT3 kinase, and TYK2 kinase. It has collaborations with Hebei Medical University Biomedical Engineering Center and Sierra Oncology, Inc. The company was founded in 2003 and is based in Cambridge, the United Kingdom.

Industry, Sector and Symbol

Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-1223-497700

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Cash FlowGBX 0.09 per share
Book ValueGBX 0.10 per share

Profitability

Miscellaneous

EmployeesN/A
Outstanding Shares2,875,990,016
Market Cap£15.10 million
Next Earnings DateN/A
OptionableNot Optionable

Receive SAR News and Ratings via Email

Sign-up to receive the latest news and ratings for SAR and its competitors with MarketBeat's FREE daily newsletter.

Sareum (LON:SAR) Frequently Asked Questions

What is Sareum's stock symbol?

Sareum trades on the London Stock Exchange (LON) under the ticker symbol "SAR."

Has Sareum been receiving favorable news coverage?

News articles about SAR stock have trended positive this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Sareum earned a daily sentiment score of 2.6 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the stock's share price in the near term. View News Stories for Sareum.

Who are some of Sareum's key competitors?

What other stocks do shareholders of Sareum own?

Who are Sareum's key executives?

Sareum's management team includes the folowing people:
  • Dr. Tim J. Mitchell, Founder, CEO & Exec. Director (Age 59)
  • Dr. John C. Reader Ph.D., Founder, Chief Scientific Officer & Exec. Director (Age 52)
  • Tony Bunn FCMA, Sec.

How do I buy shares of Sareum?

Shares of SAR and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Sareum's stock price today?

One share of SAR stock can currently be purchased for approximately GBX 0.53.

How big of a company is Sareum?

Sareum has a market capitalization of £15.10 million. View Additional Information About Sareum.

What is Sareum's official website?

The official website for Sareum is http://www.sareum.co.uk/.

How can I contact Sareum?

Sareum's mailing address is Unit 2A Langford Arch, London Road, Pampisford, CAMBRIDGE, CB22 3FX, United Kingdom. The company can be reached via phone at +44-1223-497700.


MarketBeat Community Rating for Sareum (LON SAR)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  65 (Vote Outperform)
Underperform Votes:  71 (Vote Underperform)
Total Votes:  136
MarketBeat's community ratings are surveys of what our community members think about Sareum and other stocks. Vote "Outperform" if you believe SAR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SAR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel